The experimental drug 710GO simultaneously activates two melanocortin receptors (MC3R and MC4R) in the brain's hunger control center, producing significant weight loss in obese nonhuman primates with minimal weight rebound. This dual-target approach outperformed selective MC4R activation alone, demonstrating that these receptors work cooperatively rather than redundantly to regulate metabolism and food intake. The compound is orally available and compatible with existing GLP-1 therapies like semaglutide. This represents a potentially transformative shift in obesity drug development. Previous melanocortin-based therapies targeting MC4R alone have shown disappointing clinical results, leading many pharmaceutical companies to abandon this pathway. The discovery that MC3R activation works synergistically with MC4R suggests the field may have been pursuing an incomplete strategy. While primate studies often translate well to humans, the real test will be whether 710GO can replicate these dramatic effects in human clinical trials. The melanocortin system's central role in appetite regulation makes this one of the most biologically rational targets for obesity treatment, and this dual-receptor approach could finally unlock its therapeutic potential.